早期糖皮质激素与COVID-19相关ARDS中的呼吸机相关性肺炎
该研究回顾性纳入2020年15个ICU中因COVID-19相关ARDS接受有创机械通气≥48小时的成人患者670例,按24小时内是否使用糖皮质激素分为两组(使用369例,未使用301例)。主要终点为呼吸机相关性肺炎(VAP)发生率,以死亡和拔管为竞争事件;早期糖皮质激素组VAP累积发生率更高(aHR 1.29,95%CI 1.05-1.58,P=0.016)。两组VAP细菌耐药性无差异(OR 0.94,95%CI 0.58-1.53,P=0.81)。90天死亡率早期激素组30.9% vs 未用组24.3%,校正年龄、SOFA评分和VAP发生后无显著差异(aHR 1.15,95%CI 0.83-1.60,P=0.411)。VAP与更高的90天死亡率相关(aHR 1.86,95%CI 1.33-2.61,P=0.0003)。
要点
- 早期(24小时内)糖皮质激素与COVID-19相关ARDS患者VAP风险升高相关:aHR 1.29(95%CI 1.05-1.58,P=0.016)。
- 两组VAP细菌耐药性无显著差异:OR 0.94(95%CI 0.58-1.53,P=0.81)。
- 90天死亡率早期激素组30.9% vs 未用组24.3%,校正年龄、SOFA评分和VAP后无显著差异(aHR 1.15,95%CI 0.83-1.60,P=0.411)。
- VAP与更高的90天死亡率独立相关:aHR 1.86(95%CI 1.33-2.61,P=0.0003)。
- 作者认为,需在需有创机械通气的COVID-19相关ARDS患者中开展早期糖皮质激素的纵向随机对照试验。
适用人群与场景
- 2020年15个重症监护病房中因COVID-19相关ARDS接受有创机械通气≥48小时的成人患者,共670例(平均年龄65岁)。
研究设计与关键结果
- 研究类型:回顾性多中心队列研究,纳入15个ICU的670例COVID-19相关ARDS有创机械通气≥48小时成人患者。
- 分组:根据24小时内是否使用糖皮质激素分为早期激素组369例和未用组301例。
- 主要终点:VAP累积发生率早期激素组更高(aHR 1.29,95%CI 1.05-1.58,P=0.016),死亡和拔管为竞争事件。
- VAP细菌耐药性:两组无显著差异(OR 0.94,95%CI 0.58-1.53,P=0.81)。
- 90天死亡率:早期激素组30.9% vs 未用组24.3%,校正年龄、SOFA评分和VAP发生后无显著差异(aHR 1.15,95%CI 0.83-1.60,P=0.411)。
- VAP与90天死亡率:VAP与更高的90天死亡率相关(aHR 1.86,95%CI 1.33-2.61,P=0.0003)。
证据类型、等级与局限
- 证据类型:回顾性多中心队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 在需有创机械通气的COVID-19相关ARDS患者中,早期使用糖皮质激素可能与VAP风险升高相关(aHR 1.29),临床需关注VAP的监测与预防。
- 早期糖皮质激素未显著增加90天死亡率(aHR 1.15,95%CI 0.83-1.60),但VAP本身与更高90天死亡率相关(aHR 1.86),提示发生VAP后应积极处理。
- 作者认为,需在需有创机械通气的COVID-19相关ARDS患者中开展早期糖皮质激素的纵向随机对照试验。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
RATIONALE: Early corticosteroid treatment is used to treat COVID-19-related acute respiratory distress syndrome (ARDS). Infection is a well-documented adverse effect of corticosteroid therapy.
OBJECTIVES: To determine whether early corticosteroid therapy to treat COVID-19 ARDS was associated with ventilator-associated pneumonia (VAP).
METHODS: We retrospectively included adults with COVID-19-ARDS requiring invasive mechanical ventilation (MV) for ≥ 48 h at any of 15 intensive care units in 2020. We divided the patients into two groups based on whether they did or did not receive corticosteroids within 24 h. The primary outcome was VAP incidence, with death and extubation as competing events. Secondary outcomes were day 90-mortality, MV duration, other organ dysfunctions, and VAP characteristics.
MEASUREMENTS AND MAIN RESULTS: Of 670 patients (mean age, 65 years), 369 did and 301 did not receive early corticosteroids. The cumulative VAP incidence was higher with early corticosteroids (adjusted hazard ratio [aHR] 1.29; 95% confidence interval [95% CI] 1.05-1.58; P = 0.016). Antibiotic resistance of VAP bacteria was not different between the two groups (odds ratio 0.94, 95% CI 0.58-1.53; P = 0.81). 90-day mortality was 30.9% with and 24.3% without early corticosteroids, a nonsignificant difference after adjustment on age, SOFA score, and VAP occurrence (aHR 1.15; 95% CI 0.83-1.60; P = 0.411). VAP was associated with higher 90-day mortality (aHR 1.86; 95% CI 1.33-2.61; P = 0.0003).
CONCLUSIONS: Early corticosteroid treatment was associated with VAP in patients with COVID-19-ARDS. Although VAP was associated with higher 90-day mortality, early corticosteroid treatment was not. Longitudinal randomized controlled trials of early corticosteroids in COVID-19-ARDS requiring MV are warranted.
参考来源
- Lamouche-Wilquin P, Souchard J, Pere M, et al. Early steroids and ventilator-associated pneumonia in COVID-19-related ARDS. Crit Care. 2022. PMID: 35918776. doi:10.1186/s13054-022-04097-8
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。